Home > News

Aries Pharmaceuticals and Olympus Initiate Co-Promotion of Eleview™ at the American College of Gastroenterology’s World Congress

SAN DIEGO (October 13, 2017)Aries Pharmaceuticals, Inc. (Aries), a specialty pharmaceutical company commercializing best-in-class gastroenterology products utilized in endoscopy and for the treatment of select gastrointestinal diseases, today announced it will initiate with Olympus the co-promotion of Eleview at the American College of Gastroenterology’s (ACG) World Congress in Orlando, Fla. Eleview is an FDA 510(k) cleared, ready-to-use submucosal injection composition that provides an immediate and long-lasting cushion for GI endoscopic resections of polyps, adenomas, early stage cancers, and other lesions in the gastrointestinal (GI) tract. Aries is the U.S. distribution arm of Aries Ltd., a wholly owned subsidiary of Cosmo Pharmaceuticals N.V., who developed Eleview.

Aries Pharmaceuticals, Inc. enters co-promotion agreement in the U.S. with Olympus for Eleview, a ready-to-use submucosal injection composition that provides an immediate and long-lasting cushion for GI endoscopic resections of polyps, adenomas, and other lesions.

Eleview, designed for easy and safe resection, increases visibility of target lesion margins and lowers the risk of perforation. It is appropriate for challenging polyps, regardless of size, location, or type and the immediate, long-lasting cushion can hold for up to 45 minutes. Eleview improves margin visualization and helps decrease the risk of gastrointestinal perforation and damage to the external muscular layer, which can lead to gastrointestinal perforation. Furthermore, it may decrease the time needed to resect a lesion while reducing both reinjections required and piecemeal excisions, as compared to saline.

“We are very happy to be initiating this co-promotion with our colleagues at Olympus,” said Tom Joyce, President and Chief Executive Officer of Aries. “Olympus is a global leader in endoscopy, and our joint promotion will be a significant boost for the commercial success of Eleview.”

“This innovative injection agent is a complement to our EndoTherapy portfolio and will further assist physicians during endoscopic procedures and when performing gastrointestinal resections,” said Kurt Heine, Group Vice President of the Endoscopy Division at Olympus America, Inc. “Better visibility of lesions, along with increased efficiency, can bring us closer to our goal of improving quality of care, reducing healthcare costs and enhancing patient satisfaction.”

Aries and Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, will work together to promote and sell Eleview to end-user customers and will each sell Eleview through their existing distribution networks. This combined effort will leverage both companies’ established salesforce and distribution networks to address the endoscopy market in an efficient and cost-effective manner.

To learn more about Eleview or to place an order, please call 1-888-ARIES-08 (1-888-274-3708).

About Aries Pharmaceuticals, Inc.

Aries Pharmaceuticals, Inc. (Aries) is a specialty pharmaceutical company commercializing best-in-class gastroenterology products for the United States market with a focus on products utilized in endoscopy and for the treatment of select gastrointestinal diseases. The company’s initial portfolio of four products, three of which are still in development, are licensed from Cosmo Pharmaceuticals N.V. to Aries Ltd. Aries is the US distribution arm of Aries Ltd., a wholly owned subsidiary of Cosmo Pharmaceuticals N.V. For further information on Aries, please visit the company’s website: www.ariespharma.com. Developed by Cosmo Pharmaceuticals, Eleview™ has been 510(k) cleared by the FDA as a class II medical device and is the only commercially available medical device for this indication. Additional product information is available at EleviewUS.com.

About Olympus Medical Systems Group

Olympus Medical Systems Group, a division of global technology leader Olympus, develops solutions for healthcare professionals that help improve clinical outcomes, reduce overall costs and enhance quality of life for their patients. By enabling less invasive procedures, innovative diagnostic and therapeutic endoscopy, and early stage lung cancer evaluation and treatments, Olympus is transforming the future of healthcare. For more information visit Olympus at www.medical.olympusamerica.com.

Media Contacts:

Deborah Hernandez
FKH
Vice President
617-417-6359
Deborah.Hernandez@fkhealth.com